The metabolic impact of Darunavir/ritonavir maintenance monotherapy after successful viral suppression with standard Atripla in HIV-1 infected patients: an unblinded, multicentre, randomised controlled trial

Trial Profile

The metabolic impact of Darunavir/ritonavir maintenance monotherapy after successful viral suppression with standard Atripla in HIV-1 infected patients: an unblinded, multicentre, randomised controlled trial

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2016

At a glance

  • Drugs Darunavir (Primary) ; Ritonavir (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate
  • Indications HIV-1 infections
  • Focus Pharmacodynamics
  • Acronyms MIDAs
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Oct 2015 Results published in the Antiviral Therapy
    • 13 Oct 2015 Primary endpoint (Vitamin D levels endpoint is change in 25(OH) Vitamin D) has been met as per results published in the Antiviral Therapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top